Genmab

Lundbeck will present details of its Phase 3 MASCOT trial for amlenetug, a first-in-class monoclonal antibody targeting α-synuclein aggregation in Multiple System Atrophy patients.

The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.

Genmab will acquire Merus for $97.00 per share, representing a 41% premium and totaling approximately $5.2 billion in the largest deal in Genmab's history.

The follicular lymphoma market is projected to grow at a 6% CAGR during 2025-2034, driven by increased disease awareness and rising number of clinical trials focused on this slow-growing B-cell malignancy.

Genmab and BioNTech are conducting two separate clinical trials evaluating novel antibody therapies for solid tumors, including GEN1055 monotherapy and combination treatments.

Genmab is conducting a Phase 3 trial evaluating acasunlimab combined with pembrolizumab versus docetaxel in PD-L1 positive metastatic non-small cell lung cancer patients who progressed after prior PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.

Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.

The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.

Genmab will showcase 14 abstracts evaluating epcoritamab, their subcutaneously administered T-cell engaging bispecific antibody, across multiple lymphoma settings at the 2025 EHA Congress in Milan.